Recurrent Acute Biphenotypic Leukemia

7 clinical trials · Condition

Record	Firm	Date
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 (NCT04874194)	M.D. Anderson Cancer Center	2021-12-17
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT04975919)	M.D. Anderson Cancer Center	2021-09-29
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (NCT04526795)	M.D. Anderson Cancer Center	2021-04-09
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant (NCT03807063)	Fred Hutchinson Cancer Center	2020-01-02
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04047641)	M.D. Anderson Cancer Center	2019-10-22
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921)	Fred Hutchinson Cancer Center	2018-02-23
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193)	M.D. Anderson Cancer Center	2018-01-18

Every clearance here is in the API, with alerts when new ones post.